The CFRI CF Community Voices Podcast

Dr. Janet Woodcock, Principal Deputy Commissioner of the US Food and Drug Administration, delivered Keynote Remarks at the opening of CFRI’s 35^th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Dr. Manu Jain, Professor of Medicine and Pediatrics at Northwestern University’s Feinberg School of Medicine and Director of the Adult CF Program at Northwestern, presents a comprehensive overview on mRNA therapy for people with cystic fibrosis, a mutation-agnostic treatment that could work for any person with CF regardless of their CFTR mutation. Dr. Jain provides an update on the principles behind mRNA therapy, the hurdles it faces to become a viable treatment option, and the various programs in clinical development. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Dr. Paul McCray, Professor of Pediatrics, Division of Pulmonary Medicine, and Professor of Microbiology and Immunology at the University of Iowa, presents an overview on advances in gene therapy for cystic fibrosis, with a focus on gene therapy for lung disease treatment and prevention. Dr. McCray explores the different gene addition and gene editing strategies under investigation and reviews the challenges of delivery to the lung. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Emily Kramer-Golinkoff, an adult with cystic fibrosis and the Co-Founder of Emily's Entourage, an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of CF, describes her experience growing up with CF and the heart-shattering realization that she is a part of the approximately 10% of the CF community that is ineligible for CFTR modulators. She discusses the promise of science and innovation, each individual’s power to create transformative change, and the unique solidarity and commitment of the whole CF community to create a better future for everyone with CF. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

At CFRI's virtual Conference Awards Celebration on July 30, 2022, we honored these extraordinary individuals: Richard Moss, MD - Paul M. Quinton Cystic Fibrosis Research Legacy Award; Sonya Haggett, LCSW - CFRI Partners in Living Award In Memory of Anabel Stenzel; Anna Payne – Dave Stuckert Memorial Volunteer of the Year Award; Dennis Nielson, MD, PhD - Professional of the Year Award.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Dr. Janet Woodcock, Principal Deputy Commissioner of the US Food and Drug Administration, delivered Keynote Remarks at the opening of CFRI’s 35^th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Dr. Manu Jain, Professor of Medicine and Pediatrics at Northwestern University’s Feinberg School of Medicine and Director of the Adult CF Program at Northwestern, presents a comprehensive overview on mRNA therapy for people with cystic fibrosis, a mutation-agnostic treatment that could work for any person with CF regardless of their CFTR mutation. Dr. Jain provides an update on the principles behind mRNA therapy, the hurdles it faces to become a viable treatment option, and the various programs in clinical development. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Dr. Paul McCray, Professor of Pediatrics, Division of Pulmonary Medicine, and Professor of Microbiology and Immunology at the University of Iowa, presents an overview on advances in gene therapy for cystic fibrosis, with a focus on gene therapy for lung disease treatment and prevention. Dr. McCray explores the different gene addition and gene editing strategies under investigation and reviews the challenges of delivery to the lung. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Emily Kramer-Golinkoff, an adult with cystic fibrosis and the Co-Founder of Emily's Entourage, an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of CF, describes her experience growing up with CF and the heart-shattering realization that she is a part of the approximately 10% of the CF community that is ineligible for CFTR modulators. She discusses the promise of science and innovation, each individual’s power to create transformative change, and the unique solidarity and commitment of the whole CF community to create a better future for everyone with CF. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

In this moving and informative podcast, a personal overview of life with CF in Pakistan is shared by those who live with and treat the disease. Meet two women from Pakistan who share the lack of therapies they have available to treat their disease, and from Dr. Ali Akbar, a pulmonologist in the UK who is working to raise awareness and access to care in his native Pakistan.

If you watch this episode, please let us know what you think at https://www.surveymonkey.com/r/KGB7PKY

CF Community Voices is made possible through grants from Chiesi USA, Genentech, Vertex Pharmaceuticals, Gilead Sciences, and Viatris.